APA (7th ed.) Citation

Capdevila, J., Pubul, V., Anido, U., Walter, T., Molina-Cerrillo, J., Alonso-Gordoa, T., . . . Taïeb, D. (2025). A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: The LEVEL study (GETNE T-2217). BMC Cancer, 25(1), 1. https://doi.org/10.1186/s12885-025-13941-3

Chicago Style (17th ed.) Citation

Capdevila, Jaume, et al. "A Randomized Clinical Trial Evaluating the Impact on Survival and Quality of Life of 177Lutetium[Lu]-edotreotide Versus Everolimus in Patients with Neuroendocrine Tumors of the Lung and Thymus: The LEVEL Study (GETNE T-2217)." BMC Cancer 25, no. 1 (2025): 1. https://doi.org/10.1186/s12885-025-13941-3.

MLA (9th ed.) Citation

Capdevila, Jaume, et al. "A Randomized Clinical Trial Evaluating the Impact on Survival and Quality of Life of 177Lutetium[Lu]-edotreotide Versus Everolimus in Patients with Neuroendocrine Tumors of the Lung and Thymus: The LEVEL Study (GETNE T-2217)." BMC Cancer, vol. 25, no. 1, 2025, p. 1, https://doi.org/10.1186/s12885-025-13941-3.